We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Field Evaluation of Quantitative G6PD Diagnostics Reviewed

By LabMedica International staff writers
Posted on 27 Sep 2017
Glucose-6-phosphate dehydrogenase deficiency (G6PDd) is the most common enzymopathy with at least 400 million individuals affected worldwide. More...
More than 185 clinically relevant variants of G6PDd have been reported with a spectrum of associated enzyme deficiencies.

The presence of G6PDd in patients with Plasmodium vivax infection results in significant challenges to achieving radical cure. The 8-aminoquinolone compounds are the only class of anti-malarial drugs currently available to eliminate the dormant hypnozoites liver stages of P. vivax are and these cause hemolysis in G6PDd individuals.

Scientists at the Charles Darwin University (Sydney, Australia) and their colleagues reviewed the methods for the field evaluation of quantitative G6PD diagnostics. G6PD enzyme activity and its degradation is temperature dependent, hence whole EDTA blood should not be stored at room temperature. Freezing samples and maintaining a respective cold chain in a field setting is demanding and often impossible. Whole blood samples can be stored at 4–8 °C for later analysis; however the duration at which samples can be stored and reliably assayed at a later time point is unknown. Field evaluation is based on the comparison of paired samples, including one sample tested by the new assay at point of care and one sample tested by the gold-standard reference method, UV spectrophotometry in an established laboratory.

In one study the G6PD activity of paired samples collected from venous and capillary sampling were similar when measured by spectrophotometry, the medians were 7.51 and 7.61 U/gHb, respectively. Similarly, an evaluation of qualitative tests by fluorescent spot test (FST) and Carestart G6PD RDT showed 100% concordance between paired capillary and venous samples. ACCESS BIO has recently developed a Biosensor, a quantitative handheld device that measures G6PD activity based on the electrochemical properties of G6PD in blood samples.

The WST8/1-methoxy PMS test is a robust and cost effective alternative to estimate G6PD activity that can be performed on dried blood spots and whole blood samples. The WST8/1 test is based on the formation of an orange formazan dye generated by G6PD enzyme activity and facilitated by the 1-methoxy PMS as an electron carrier. The assay has been adapted for quantitative batch testing in a 96 well microplate and can be read by an enzyme-linked immunosorbent assay (ELISA) reader.

The authors concluded that their review presented a number of recommendations to facilitate standardized evaluation of quantitative G6PD activity test assays. Standardized evaluation studies are necessary to provide a comparable basis for subsequent pooled analyses. As novel quantitative G6PD diagnostics become available their potential to provide robust quantitative G6PD results suitable for field deployment needs to be assessed. The most recent generation of instruments contain an integrated temperature correction factor and hemoglobin measurement and G6PD activity is displayed normalized as U/gHb. The study was published on September 11, 2017, in the Malaria Journal.

Related Links:
Charles Darwin University



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Microscope
dIFine
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.